Provides personalized medicine care through pharmaceutical compounding. Innovates concepts, vehicles, and formulations for pharmaceutical compounding. Now — the numbers.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It pays out $0.46 per share each year — regular cash for whoever holds the stock.
Getting in and out without moving the price could prove difficult.
Against everything we grade, ARSUF lands somewhere in the middle. The grade moves as the numbers move.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.